[{"address1": "2617 Bissonnet Street", "address2": "Suite 225", "city": "Houston", "state": "TX", "zip": "77005", "country": "United States", "phone": "346 355 4099", "website": "https://www.alaunos.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.", "fullTimeEmployees": 1, "companyOfficers": [{"maxAge": 1, "name": "Mr. Dale Curtis Hogue Jr.", "age": 53, "title": "Interim CEO & Director", "yearBorn": 1970, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melinda  Lackey", "age": 46, "title": "Senior VP of Legal, Administration & Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 625117, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Wong", "age": 43, "title": "Vice President of Finance & Principal Accounting Officer", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 3, "overallRisk": 6, "governanceEpochDate": 1726617600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.35, "open": 3.49, "dayLow": 3.36, "dayHigh": 4.18, "regularMarketPreviousClose": 3.35, "regularMarketOpen": 3.49, "regularMarketDayLow": 3.36, "regularMarketDayHigh": 4.18, "beta": -0.556, "forwardPE": -6.5666666, "volume": 102035, "regularMarketVolume": 102035, "averageVolume": 22026, "averageVolume10days": 38420, "averageDailyVolume10Day": 38420, "bid": 3.25, "ask": 4.51, "bidSize": 100, "askSize": 100, "marketCap": 6308925, "fiftyTwoWeekLow": 2.07, "fiftyTwoWeekHigh": 33.0, "priceToSalesTrailing12Months": 901.275, "fiftyDayAverage": 2.9898, "twoHundredDayAverage": 11.58595, "currency": "USD", "enterpriseValue": 3845933, "floatShares": 1308207, "sharesOutstanding": 1601250, "sharesShort": 139653, "sharesShortPriorMonth": 144061, "sharesShortPreviousMonthDate": 1722384000, "dateShortInterest": 1724976000, "sharesPercentSharesOut": 0.0872, "heldPercentInsiders": 0.14297, "heldPercentInstitutions": 0.15215999, "shortRatio": 7.19, "shortPercentOfFloat": 0.1013, "bookValue": 2.355, "priceToBook": 1.6730361, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -19129000, "trailingEps": -319.97, "forwardEps": -0.6, "enterpriseToRevenue": 549.419, "enterpriseToEbitda": -0.306, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TCRT", "underlyingSymbol": "TCRT", "shortName": "Alaunos Therapeutics, Inc.", "longName": "Alaunos Therapeutics, Inc.", "firstTradeDateEpochUtc": 1124890200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "05ce1922-a43a-368b-a87c-0906e2ee068e", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.94, "recommendationMean": 3.0, "recommendationKey": "hold", "totalCash": 2463000, "totalCashPerShare": 1.538, "ebitda": -12579000, "quickRatio": 2.72, "currentRatio": 5.158, "totalRevenue": 7000, "revenuePerShare": 0.004, "returnOnAssets": -0.51764, "returnOnEquity": -1.50498, "freeCashflow": -11826750, "operatingCashflow": -17357000, "operatingMargins": -291.5, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-26"}]